About this event
Join us for this unique 3-part webinar series, as we discover the role of genetics and genomics in modern drug discovery and determine how we can better leverage ever-improving technologies for patient benefit.
Tuesday 10th May at 3pm BST/4pm CET/10am EST
Since it was discovered that drug targets with a genetic basis are twice as likely to be approved, drug discovers have been turning to the genome in search of their latest target.
In this webinar, we explore how drug hunters are fuelling the next era of research with the power of genomics and other omics, to unlock new drugs and bring therapies closer to the patient
Therapeutic Discovery Platform Supported by Computational Biology - Jun Yin, Associate Director, Bioinformatics, Ferring Pharmaceuticals
Translational biomarkers: using genomics to define combination therapy in cancer patients - Tereza Vaclova, Senior Scientist, AstraZeneca
It’s a protein world: proteomics applications for drug discovery - Yann Abraham, Senior Principal Data Scientist for the AI/Genomics Initiative, Janssen
Tuesday 17th May at 3pm BST/4pm CET/10am EST
Targeting genetic perturbations and screening for phenotypes of interest has been made easy with the implementation of CRISPR-based genome editing. Currently there are limited studies that benchmark methods for gene-level hits from genome-wide CRISPR screens. This webinar focuses on the challenges of CRISPR screening and their implementation within genomic-based drug discovery.
Applications of arrayed CRISPR screens for target identification in drug discovery -Lishu Duan, Principal Scientist I - In Vitro Pharmacology, AbbVie
The Power of Single Cell and CRISPR Screening - Stephen Hague, Managing Lead Science & Technology Advisor EMEA, 10x Genomics
A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system – Fredrik Wermeling, Associate Professor, Karolinska Institute
Tuesday 24th May at 3pm BST/4pm CET/10am EST
Increasingly large volumes of data are being collected using different genomic technologies and data science approaches. With growing data collection, there is an increased need for new integration methods and algorithms. Join us to discover new advances within multi-omics ‘big data’ and the implementation of computational methods for genomic-driven drug discovery.
Using Omicsfold to integrate, mine and infer new insights from multiomic big data - Shameer Khader, Senior Director (AI/ML, Data Science, Digital Health and Bioinformatics), AstraZeneca
Integrating public and commercial datasets and interpretation guidelines for genomic data analysis – Alex Joyner, Application Scientist, VarSome
Using Varsome Annotation for Disease Burden Estimation and Variants Prioritization – Star Chen, Scientist (Data Science), Agios and Sean Corbett, Scientist, Agios
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events and webinars. We also produce reports and operate a content-rich website.
Share this event